Personalized Management Approaches in Lymphoma: Utility of Fluorodeoxyglucose-PET Imaging.

PET Clin

Department of Hematology/Oncology, Perelman Center for Advanced Medicine, West Pavilion, 2nd Floor, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. Electronic address:

Published: July 2016

PET/computed tomography (CT) imaging has gained a prominent role in the diagnosis and staging of malignancies. In lymphoma the role of PET/CT imaging continues to evolve as the understanding of its use in prognostication and response assessment improves. Currently, many groups are studying the potential function of PET/CT imaging in helping to direct management decisions for treating clinicians. This article summarizes the most up-to-date literature surrounding the topic of PET/CT-adaptive treatment of different lymphoma subjects. Although more studies are necessary to solidify the role of PET/CT, it is clear that this imaging modality holds much promise for the development of response-adaptive treatment algorithms in the future.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpet.2016.02.001DOI Listing

Publication Analysis

Top Keywords

role pet/ct
8
pet/ct imaging
8
imaging
5
personalized management
4
management approaches
4
approaches lymphoma
4
lymphoma utility
4
utility fluorodeoxyglucose-pet
4
fluorodeoxyglucose-pet imaging
4
imaging pet/computed
4

Similar Publications

PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging.

JAMA Netw Open

January 2025

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.

Importance: The phase 3 randomized EMBARK trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive prostate cancer. Eligibility relied on conventional imaging, which underdetects metastatic disease compared with prostate-specific membrane antigen-positron emission tomography (PSMA-PET).

Objective: To describe the staging information obtained by PSMA-PET/computed tomography (PSMA-PET/CT) in a patient cohort eligible for the EMBARK trial.

View Article and Find Full Text PDF

Introduction: Anorectal melanoma (ARM) is rare and highly lethal neoplasm. It has a poorer prognosis compared with cutaneous ones. Sentinel lymph node biopsy (SLNB) has become the preferred method of nodal staging method for cutaneous melanoma.

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Yale University, New Haven, CT, USA.

Background: Advances in Alzheimer's disease (AD) have revealed a novel fluid biomarker, tau phosphorylated at T217 (pT217-tau), in CSF and plasma, that predicts AD prior to cognitive deficits. Understanding the role of pT217-tau is important in assessing efficacy of novel treatments aimed at early-stage disease. However, it is unknown why pT217-tau is effective in predicting brain pathology, as little is known about early, soluble pT217-tau brain expression.

View Article and Find Full Text PDF

Background: The accumulation of misfolded tau proteins, an Alzheimer's disease (AD) hallmark, starts decades before the emergence of cognitive decline and clinical diagnosis. Autopsy studies support a predictable progression of tau pathology through large-scale systems. However, less is known about the specific progression patterns.

View Article and Find Full Text PDF

Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization.

Cancer Biol Med

January 2025

Department of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.

Artificial intelligence (AI) is significantly advancing precision medicine, particularly in the fields of immunogenomics, radiomics, and pathomics. In immunogenomics, AI can process vast amounts of genomic and multi-omic data to identify biomarkers associated with immunotherapy responses and disease prognosis, thus providing strong support for personalized treatments. In radiomics, AI can analyze high-dimensional features from computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT) images to discover imaging biomarkers associated with tumor heterogeneity, treatment response, and disease progression, thereby enabling non-invasive, real-time assessments for personalized therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!